ImmunityBio Inc (NASDAQ:IBRX) shares rose 8.6% in premarket trading Wednesday after the company announced the FDA accepted its supplemental Biologics License Application for ANKTIVA in combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results